drugset / Trial / NCT06816043

A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants

NCT06816043

Phase 1 Completed 20 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelBasic science

Summary

The goal of this study is to learn what happens to MK-8527 in a healthy person's body over time, called a pharmacokinetic (PK) study. Researchers want to learn if there is a difference in the healthy person's body when MK-8527 is taken as a single dose (Treatment A) or with the medication Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) (Treatment B).

Timeline

Start
2025-02-21
Primary completion
2025-06-05
Completion
2025-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject FTC/TDF Unknown Oral
Subject MK-8527 Small molecule Oral

Indications

No indication recorded.